Journal
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcimb.2022.816238
Keywords
hepatitis C virus; nucleic acid detection; point-of-care testing; recombinase-aided amplification; lateral flow dipstick
Categories
Funding
- Science and Technology Project of Henan Province [212102310180]
- Open Project of National Health Commission Key Laboratory of Birth Defects Prevention [ZD202106]
- Scientific and Technological Innovation Team Plan of Henan Province [19IRTSTHN006]
Ask authors/readers for more resources
This study established a RT-RAA-LFD assay for the rapid clinical detection of HCV, which demonstrated fast, accurate, and highly specific results, making it suitable for use in communities and remote areas.
Hepatitis C virus (HCV) infection is a global public health threat. Reaching the World Health Organization's objective for eliminating viral hepatitis by 2030 will require a precise disease diagnosis. While immunoassays and qPCR play a significant role in detecting HCV, rapid and accurate point-of-care testing is important for pathogen identification. This study establishes a reverse transcription recombinase-aided amplification-lateral flow dipstick (RT-RAA-LFD) assay to detect HCV. The intact workflow was completed within 30 min, and the detection limit for synthesized C/E1 plasmid gene-containing plasmid was 10 copies/mu l. In addition, the test showed good specificity, with no cross-reactivity observed for hepatitis A virus, hepatitis B virus, HIV, syphilis, and human papillomavirus virus. Using extracted RNAs from 46 anti-HCV antibody-positive samples, RT-RAA-LFD showed 100% positive and negative concordance rates with qPCR. In summary, the RT-RAA-LFD assay established in this study is suitable for the rapid clinical detection of HCV at the community level and in remote areas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available